TY - JOUR
T1 - Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
AU - Haan, Jurre den
AU - van de Kreeke, Jacoba A.
AU - Konijnenberg, Elles
AU - Kate, Mara ten
AU - Braber, Anouk den
AU - Barkhof, Frederik
AU - van Berckel, Bart N.
AU - Teunissen, Charlotte E.
AU - Scheltens, Philip
AU - Visser, Pieter Jelle
AU - Verbraak, Frank D.
AU - Bouwman, Femke H.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.
AB - Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD). We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders. Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls. All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease. Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD. We found significant associations between macular thickness and global cortical atrophy [β −0.358; P =.01] and parietal cortical atrophy on magnetic resonance imaging [β −0.371; P <.01] in AD cases. Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.
KW - Alzheimer's disease
KW - Biomarker
KW - Cortical atrophy
KW - Neurodegeneration
KW - Retinal thickness
UR - http://www.scopus.com/inward/record.url?scp=85067274196&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.dadm.2019.05.002
DO - https://doi.org/10.1016/j.dadm.2019.05.002
M3 - Article
C2 - 31249859
SN - 2352-8729
VL - 11
SP - 463
EP - 471
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
ER -